Differences in Expression of EGFR, Ki67 and p-EPK in Oral Cavity Squamous Cell Carcinoma

Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer

“…A relevant proportion of HPV-positive OPC patients may enjoy a favorable prognosis due to molecular determinants related to good response to radiotherapy and radiochemotherapy, such as low EGFR expression [22][23][24]. It has been shown, in fact, that EGFR is expressed at lower levels in HPV-positive oropharyngeal and oral cancer patients compared to the HPV-negative ones [22,[24][25][26], and this has a favorable impact on prognosis after radio-or radiochemotherapy treatment [22,23]. Furthermore, it is known that the expression of the HER family of proteins may explain the attenuation of the antiproliferative effects of CDDP [27].…”